Silas Inman

The combination of abiraterone acetate and prednisone has demonstrated a statistically significant improvement in overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) who had not received prior treatment with chemotherapy

Treatment with crizotinib (Xalkori) demonstrated an overall response rate (ORR) of 72% in patients with ROS1-rearranged non–small cell lung cancer (NSCLC), according to phase I data presented at the 2014 ESMO Congress and published in The New England Journal of Medicine.

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab (Opdivo) as a treatment for pretreated patients with advanced melanoma.

Treatment with the combination of bevacizumab and chemotherapy improved PFS and OS in women with HER2-negative metastatic breast cancer.

The combination of ABT-199 and ibrutinib (Imbruvica) demonstrated promising early activity in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) cell lines

A Biologics License Application has been submitted to the FDA for the bispecific T-cell engager (BiTE) antibody blinatumomab as a treatment for adult patients with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

Treatment strategies that incorporate pertuzumab (Perjeta) continue to evolve as more clinical trial data becomes available.

High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

The combination of ramucirumab and FOLFIRI significantly improved OS and PFS compared with chemotherapy alone as a second-line treatment for patients with mCRC.

The FDA has expanded the approval for enzalutamide to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

The FDA has approved pembrolizumab (Keytruda) as a treatment for patients with advanced or unresectable melanoma who are no longer responding to other drugs, making it the first PD-1 inhibitor to gain approval in the United States.

Gastric cancer is comprised of 4 distinct molecular subtypes of disease, each representing a unique opportunity for new drug development, according to a paper published in Nature by The Cancer Genome Atlas (TCGA).

The FDA has assigned a priority review designation to lanreotide (Somatuline Depot) as a treatment for patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)

The combination of multiple independent factors minimized the impact of baseline stage for predicting locoregional recurrence (LRR) following neoadjuvant chemotherapy in patients with breast cancer, according to a large retrospective analysis presented in advance of the 2014 Breast Cancer Symposium.

Cabozantinib (Cometriq) failed to significantly extend overall survival compared with prednisone as a treatment for men with metastatic castration-resistant prostate cancer.

Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.

Treatment with KTE-C19, a CD19-targeted CAR-modified T cell therapy, demonstrated an objective response rate of 92% in patients with advanced B-cell malignancies.

The FDA has approved eltrombopag as a treatment for patients with severe aplastic anemia following an insufficient response to immunosuppressive therapy.

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

The addition of lenalidomide to R-CHOP demonstrated promising efficacy in previously untreated patients with diffuse large B-cell lymphoma across all subtypes of the disease.

Pfizer has submitted a New Drug Application for palbociclib plus letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative advanced breast cancer, based on findings from the phase II PALOMA-1 trial.

The FDA has approved bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Treatment with single-agent carfilzomib (Kyprolis) was unable to significantly extend overall survival (OS) compared with best supportive care in heavily pretreated patients with multiple myeloma

The FDA has approved the noninvasive stool-based DNA test Cologuard for the detection of colorectal cancer or cancer precursors in asymptomatic patients at average risk.

The FDA has expanded the bortezomib (Velcade) label to allow for retreatment in patients with multiple myeloma who previously responded to the proteasome inhibitor, according to an announcement made by Millennium/Takeda, the companies that manufacture the drug.

Women harboring a loss-of-function mutation in the PALB2 gene demonstrated an increased risk of developing breast cancer that was similar to the predisposition seen with mutations in the infamous BRCA gene

The FDA has assigned a priority review designation to the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone extended progression-free survival (PFS) by 8.7 months compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma

New generations of potent ALK inhibitors have been designed with extensive CNS activity and the ability to overcome acquired resistance mutations.

Third generation EGFR TKIs have demonstrated dramatic benefits for patients with non-small cell lung cancer (NSCLC) and should be considered as a standard second-line option following resistance to frontline therapy